

A systematic review of targeted agents for non-small ce

Acta Oncol³gica

57, 176-186

DOI: 10.1080/0284186x.2017.1404634

Citation Report

#	ARTICLE	IF	CITATIONS
1	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry â€” Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1851-1863.	0.5	6
2	MORC2 Enhances Tumor Growth by Promoting Angiogenesis and Tumor-Associated Macrophage Recruitment via Wnt/ β -Catenin in Lung Cancer. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 1679-1694.	1.1	22
3	Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment. <i>Cancers</i> , 2018, 10, 375.	1.7	5
4	<p>Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8779-8787.	1.0	5
5	Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 112.	1.0	7
6	miRâ€”221â€”3p promotes the cell growth of nonâ€”small cell lung cancer by targeting p27. <i>Molecular Medicine Reports</i> , 2019, 20, 604-612.	1.1	25
7	MicroRNAâ€”331â€”p inhibits epithelialâ€”mesenchymal transition by targeting ErbB2 and VAV2 through the Rac1/PAK1/ β -catenin axis in nonâ€”smallâ€”cell lung cancer. <i>Cancer Science</i> , 2019, 110, 1883-1896.	1.7	50
8	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	0.6	78
9	Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells. <i>International Journal of Biological Sciences</i> , 2019, 15, 826-837.	2.6	46
10	SUMO1P3 is associated clinical progression and facilitates cell migration and invasion through regulating miR-136 in non-small cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108686.	2.5	22
11	Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report. <i>BMC Cancer</i> , 2019, 19, 131.	1.1	7
12	Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib. <i>ACG Case Reports Journal</i> , 2019, 6, e00011.	0.2	8
13	Patient monitoring programs in oncology pharmacy practice: A survey of oncology pharmacists in Atlantic Canada. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 891-895.	0.5	5
14	Downregulation of miRâ€”33b promotes nonâ€”small cell lung cancer cell growth through reprogramming glucose metabolism miRâ€”33b regulates nonâ€”small cell lung cancer cell growth. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 6651-6660.	1.2	34
15	Inhalable functional mixed-polymer microspheres to enhance doxorubicin release behavior for lung cancer treatment. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 196, 111350.	2.5	14
16	Efficacy and safety of immune checkpoint inhibitors in patients with advanced nonâ€”small cell lung cancer (NSCLC): a systematic literature review. <i>OncoImmunology</i> , 2020, 9, 1774314.	2.1	34
17	Epigenetic Input Dictates the Threshold of Targeting of the Integrin-Dependent Pathway in Non-small Cell Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 652.	1.8	10
18	<p>MiR-26a-5p Serves as an Oncogenic MicroRNA in Non-Small Cell Lung Cancer by Targeting FAF1</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7131-7142.	0.9	17

#	ARTICLE	IF	CITATIONS
19	GDC-0349 inhibits non-small cell lung cancer cell growth. <i>Cell Death and Disease</i> , 2020, 11, 951.	2.7	16
20	Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2051-2066.	1.2	67
21	Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2277-2287.	1.2	11
22	MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression. <i>Cancer Letters</i> , 2020, 476, 129-139.	3.2	21
23	CircRNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 477-488.	2.1	39
24	Predicting Incomplete Resection in Non-Small Cell Lung Cancer Preoperatively: A Validated Nomogram. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1052-1058.	0.7	8
25	A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1286, 49-64.	0.8	8
26	Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. <i>Translational Lung Cancer Research</i> , 2021, 10, 1525-1535.	1.3	11
27	Silencing SIX1 by miR-7160 inhibits non-small cell lung cancer cell growth. <i>Aging</i> , 2021, 13, 8055-8067.	1.4	1
28	The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620. <i>Frontiers in Oncology</i> , 2021, 11, 669518.	1.3	19
29	The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth. <i>Cell Death and Disease</i> , 2021, 12, 751.	2.7	22
30	How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103459.	2.0	4
31	Provider decision regretâ€”a useful method for analysis of palliative thoracic re-irradiation for lung cancer?. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 315-324.	1.0	5
32	Esculetin inhibits the proliferation of human lung cancer cells by targeting epithelial-to-mesenchymal transition of the cells. <i>Cellular and Molecular Biology</i> , 2019, 65, 95-98.	0.3	8
33	miR-5582-5p inhibits cell proliferation of non-small cell lung cancer through targeting FGF-10. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 1087-1094.	0.5	4
34	Long Non-Coding RNA THOR Depletion Inhibits Human Non-Small Cell Lung Cancer Cell Growth. <i>Frontiers in Oncology</i> , 2021, 11, 756148.	1.3	9
35	Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence. <i>Cancers</i> , 2022, 14, 976.	1.7	46
41	Three-Dimensional Topological Radiogenomics of Epidermal Growth Factor Receptor Del19 and L858R Mutation Subtypes on Computed Tomography Images of Lung Cancer Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
42	HBO1 induces histone acetylation and is important for non-small cell lung cancer cell growth. <i>International Journal of Biological Sciences</i> , 2022, 18, 3313-3323.	2.6	12
43	An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	4
44	The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	3
45	Identification of the mitochondrial protein ADCK2 as a therapeutic oncotarget of NSCLC. <i>International Journal of Biological Sciences</i> , 2022, 18, 6163-6175.	2.6	5
46	Targeting the DNA Damage Response Machinery for Lung Cancer Treatment. <i>Pharmaceuticals</i> , 2022, 15, 1475.	1.7	6
47	Association Between Age and Survival Trends in Advanced Nonâ€“Small Cell Lung Cancer After Adoption of Immunotherapy. <i>JAMA Oncology</i> , 2023, 9, 334.	3.4	15
48	The mitochondrial protein YME1 Like 1 is important for non-small cell lung cancer cell growth. <i>International Journal of Biological Sciences</i> , 2023, 19, 1778-1790.	2.6	2
49	Three-dimensional topological radiogenomics of epidermal growth factor receptor Del19 and L858R mutation subtypes on computed tomography images of lung cancer patients. <i>Computer Methods and Programs in Biomedicine</i> , 2023, , 107544.	2.6	1